J9286 Injection glofitamab gxbm, 2.5 milligrams
Also known as: glofitamab, Glofitamab
Injection of glofitamab gxbm, 2.5 milligram. A bispecific T-cell engaging antibody (CD20 x CD3) for B-cell lymphoma.
In Plain Language
lymphoma immune injection; T-cell engaging therapy
Clinical Context
Used for relapsed/refractory B-cell non-Hodgkin lymphoma. Bispecific antibody engages T-cells to CD20-positive B lymphoma cells.
RVU Information
CPT J9286 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J9286?
CPT J9286 (Injection glofitamab gxbm, 2.5 milligrams) is a J Codes (Drugs) code. Injection of glofitamab gxbm, 2.5 milligram. A bispecific T-cell engaging antibody (CD20 x CD3) for B-cell lymphoma.
How is J9286 administered?
CPT J9286 is administered by a healthcare provider, typically via injection or infusion. Used for relapsed/refractory B-cell non-Hodgkin lymphoma. Bispecific antibody engages T-cells to CD20-positive B lymphoma cells. It is used by Oncology, Hematology, Immunology.
When is CPT J9286 used?
Used for relapsed/refractory B-cell non-Hodgkin lymphoma. Bispecific antibody engages T-cells to CD20-positive B lymphoma cells.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.